Biotechnology

NewcelX

NewcelX released FY2025 Q3 earnings on April 29 (EST) with actual revenue of USD 0 and EPS of USD 0.575

NewcelX released FY2025 9 Months earnings on April 29 (EST), actual revenue USD 0, actual EPS USD -2.0629

NewcelX released FY2025 Q4 earnings on April 29 Post-Market (EST), actual revenue USD 0, actual EPS USD 0.6448

NewcelX released FY2025 Annual Earnings on April 29 (EST), with actual revenue of USD 0 and EPS of USD -2.1599

NewcelX Submits Patent Application for Novel Compound DOXA in China

NewcelX Advances Clinical Trials and Announces Strategic and Clinical Progress

Kadimastem Ltd released FY2025 Semi-Annual earnings on August 31, 2025, EST with actual revenue of USD 0 and EPS of USD -2.6379

Kadimastem Ltd released FY2024 Q1 earnings on August 31, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.149

Kadimastem Ltd released FY2024 Q2 earnings on August 31, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.1456

Kadimastem Ltd released FY2024 Semi-Annual earnings on August 31 (EST), actual revenue USD 0, actual EPS USD -0.2947

Kadimastem Ltd released FY2025 Q2 earnings on August 31 (EST), actual revenue USD 0, actual EPS USD -1.3762

Kadimastem Ltd released FY2025 Q1 earnings on August 31 (EST), actual revenue USD 0, actual EPS USD -1.2616

Kadimastem Ltd released FY2024 9 Months Earnings on March 31 (EST), actual revenue USD 0, actual EPS USD -0.9977

Kadimastem Ltd released FY2024 Annual Earnings on March 31, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.7063

Kadimastem Ltd released FY2024 Q4 earnings on March 31, 2025 (EST), actual revenue USD 0, actual EPS USD -0.7174

Kadimastem Ltd released FY2023 Q4 earnings on March 31, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.1633

Kadimastem Ltd released FY2023 Q3 earnings on March 31, 2025 (EST), actual revenue USD 0, actual EPS USD -0.1544

Kadimastem Ltd released FY2023 Annual Earnings on March 31 (EST), Actual Revenue: USD 0, Actual EPS: USD -0.7769

Kadimastem Ltd released FY2024 Q3 earnings on March 31 (EST), actual revenue USD 0, actual EPS USD -0.7029

Kadimastem Ltd released FY2022 Q4 earnings on March 31, 2025 (EST), actual revenue USD 0, actual EPS USD -0.4061

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Akanda

Netcapital

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Agape ATP

NewGenIvf

Co-Diagnostics

Tradr 2X Long QBTS Daily ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

NCEL

NewcelX fell 16.10%; Amgen fell 4.89%, with a trading volume of USD 375 million; Cue BioPharma rose 97.52%, with a trading volume of USD 375 million; AbbVie fell 0.40%, with a trading volume of USD 324 million; Gilead Sciences fell 0.07%, with a market capitalization of USD 162.3 billion

Price Alert

Amgen

Cue BioPharma

Abbvie

Gilead Sciences

U.S. stock market update: NewcelX down 16.10%, financial losses and worsening financing environment raise market concerns

NewcelX shares are trading higher after the company reported a year-over-year increase in FY EPS results. The company announced it expects to expand development collaborations for Diabetes drugs in 2026.

benzinga_article

NEWCELX LTD C/WTS 02/02/2026(TO PUR COM)

NewcelX Ltd. (NASDAQ:NCEL) reported its 2025 financial results, highlighting progress in its Type 1 diabetes program, NCEL-101, and plans for accelerated execution in 2026. The company raised $1.35 million in financing, with potential additional proceeds of $2.0 million. NewcelX aims to advance NCEL-101 through IND-enabling activities and enhance its pipeline, including AstroRx for ALS. The company expects 2026 to focus on key milestones, collaborations, and funding, with shares rising 7.89% to $3.69 in premarket trading.

Eledon Pharmaceuticals

Pluri

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | NCEL Stock News

StockTitan

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | NCEL Stock News

NewcelX (NCEL) insiders have made significant share purchases, with Director Samuel Olivier buying 81,818 shares for $224,999 and CSO Michel Revel acquiring 54,545 shares for $149,998. These transactions may indicate confidence in the company's future. Recent updates highlight NCEL-101 as central to its Type 1 diabetes strategy and a collaboration with Eledon for improved graft survival. The stock has seen a year-to-date price increase of 76.32%, with a current market cap of $17.64M, amidst a challenging biotech financing environment.

Tip Ranks

Top NewcelX Insiders Quietly Make Bold Moves With Fresh Share Purchases

REPL

CPIX

In Thursday's trading session, several health care stocks experienced significant movements. EUDA Health Holdings surged 127.5% to $13.74, while Cumberland Pharma rose 23.6% to $3.77. Other gainers included NewcelX (+22.4%), Replimune Group (+18.72%), cbdMD (+16.66%), and Citius Pharmaceuticals (+15.94%). Conversely, SILO Pharma dropped 25.4% to $0.43, Medpace Holdings fell 22.98% to $391.63, and Alpha Compute decreased 21.48% to $0.18. Other notable losers included Icecure Medical, Altimmune, and Axe Compute.

Replimune

Alpha Compute

Cumberland Pharma

Silo Pharma

Medpace

Icecure Medical

Health Care Select Sector SPDR

iShares US Healthcare Providers

SPDR S&P Health

VG Health

Euda Health

cbdMD

Citius Pharma

Altimmune

Axe Compute

Euda Health - CW22

CBDMD INC 8% SERIES A CUM CONVERT PFD STK USD25

12 Health Care Stocks Moving In Thursday's Intraday Session

ELDN

NewcelX Ltd. (Nasdaq: NCEL) has updated its corporate presentation to emphasize its strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and the advancement of its flagship Type 1 Diabetes program, NCEL-101. This collaboration integrates NewcelX’s stem-cell-derived islet replacement platform with Eledon’s immune-modulation therapy, aiming to enhance graft survival and potentially provide a functional cure for Type 1 Diabetes. The updated presentation will be showcased at the Swiss Biotech Conference, highlighting NewcelX's development strategy and vision for the program.

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference | NCEL Stock News

NewcelX(NCEL.US)

U.S. stock market update: NewcelX down 16.10%, financial losses and worsening financing environment raise market concerns

NewcelX shares are trading higher after the company reported a year-over-year increase in FY EPS results. The company announced it expects to expand development collaborations for Diabetes drugs in 2026.

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | NCEL Stock News

Top NewcelX Insiders Quietly Make Bold Moves With Fresh Share Purchases

12 Health Care Stocks Moving In Thursday's Intraday Session

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference | NCEL Stock News